Annovis Bio shares are trading lower after the company announced data from its Phase II/III Alzheimer study of buntanetap in mild to moderate Alzheimer's. Efficacy in the CGIC endpoint was not reached due to the limited number of patients and shor...
Annovis Bio -1.93%
Annovis Bio ANVS | 9.63 | -1.93% |
Annovis Bio shares are trading lower after the company announced data from its Phase II/III Alzheimer study of buntanetap in mild to moderate Alzheimer's. Efficacy in the CGIC endpoint was not reached due to the limited number of patients and short trial duration.